Calendar

Week of Apr 27, 2026

Apr 30, 2026filing121d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026phase 0 trial completion121d agoKunming Yan'an Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

Therapy area: Central Nervous System. Indication: Pain

full page →dexmedetomidine →source: globaldata

Apr 30, 2026phase 0 trial completion121d agoRuijin Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

Therapy area: Central Nervous System, Dermatology. Indication: Burns, Pain, Sedation

full page →dexmedetomidine →source: globaldata

Apr 30, 2026phase 0 trial completion121d agoSecond Affiliated Hospital of Anhui Medical University — yingtao shujie paste (Phase 0 Trial Completion)yingtao shujie paste

Therapy area: Oncology, Women's Health. Indication: Breast Cancer, Breast Hyperplasia

full page →yingtao shujie paste →source: globaldata

Apr 30, 2026phase 0 trial completion121d agoShanghai Jiao Tong University — insulin (Phase 0 Trial Completion)insulin

Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

full page →insulin →source: globaldata

Apr 30, 2026phase 0 trial completion121d agoFoundation for the Promotion of Health and Biomedical Research of Valencia — Aquacel Ag + (Phase 0 Trial Completion)Aquacel Ag +

Therapy area: Dermatology. Indication: Pressure Ulcers

full page →Aquacel Ag + →source: globaldata

Apr 30, 2026phase 1 completion121d agoIlife Consulting Sarl — PST-611 (Phase I Trial Completion)PST-611

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Dry (Atrophic) Macular Degeneration, Geographic Atrophy

full page →PST-611 →source: globaldata

Apr 30, 2026phase 1 completion121d agoEcolab Inc — (acetaminophen + ibuprofen) (Phase I Trial Completion)(acetaminophen + ibuprofen)

Therapy area: Central Nervous System, Ear Nose Throat Disorders, Hormonal Disorders, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Ankylosing Spondylitis (Bekhterev's Disease), Dental Pain (Toothache/Tooth Pain), Fever, Fibromyalgia (Fibromyalgia Syndrome), Gouty Arthritis (Gout), Hyperthyroidism, Laryngitis, Low Back Pain, Mixed Pain (Nociceptive Pain/Neuropathic Pain), Musculoskeletal Inflammation, Musculoskeletal Pain, Myalgia (Muscle Pain), Neuropathic Pa

full page →(acetaminophen + ibuprofen) →source: globaldata

Apr 30, 2026phase 1 initiation121d agoJiangsu Vcare PharmaTech Co Ltd — VC-005 (Phase I Trial Initiation)VC-005

Therapy area: Dermatology. Indication: Atopic Dermatitis (Atopic Eczema)

full page →VC-005 →source: globaldata

Apr 30, 2026phase 1 initiation121d agoMerck & Co Inc — MK-6050 (Phase I Trial Initiation)MK-6050

Therapy area: Dermatology. Indication: Hidradenitis Suppurativa

full page →MK-6050 →source: globaldata

Apr 30, 2026phase 1 2 completion121d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 1 2 completion121d agoCentre International de Développement Pharmaceutique — afamelanotide (Phase I/II Trial Completion)afamelanotide

Therapy area: Dermatology. Indication: Vitiligo

full page →afamelanotide →source: globaldata

Apr 30, 2026phase 1 2 completion121d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

full page →MK-8748 →source: globaldata

Apr 30, 2026phase 2 completion121d agoUniversity of Benin Teaching Hospital — doxycycline (Phase II Trial Completion)doxycycline ER

Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

full page →doxycycline ER →source: globaldata

Apr 30, 2026phase 2 completion121d agoVaidya Yagya Dutt Sharma Ayurvedic P. G. Mahavidhyalaya — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

Therapy area: Dermatology. Indication: Burns

full page →ayurvedic medicine →source: globaldata

Apr 30, 2026phase 2 completion121d agoNational Health and Medical Research Council — docosahexaenoic acid (Phase II Trial Completion)docosahexaenoic acid

Therapy area: Women's Health. Indication: Labor And Delivery

full page →docosahexaenoic acid →source: globaldata

Apr 30, 2026phase 2 completion121d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata

Apr 30, 2026phase 2 completion121d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

full page →ozonated oil →source: globaldata

Apr 30, 2026phase 2 completion121d agoTaian City Central Hospital — alfentanil (Phase II Trial Completion)alfentanil

Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

full page →alfentanil →source: globaldata

Apr 30, 2026phase 2 completion121d agoAssaf Harofeh Medical Center — acetaminophen (Phase II Trial Completion)acetaminophen ER

Therapy area: Central Nervous System. Indication: Pain

full page →acetaminophen ER →source: globaldata

Apr 30, 2026phase 2 completion121d agoCentrum Clinic IVF Center — follitropin (Phase II Trial Completion)follitropin

Therapy area: Women's Health. Indication: Female Infertility

full page →follitropin →source: globaldata

Apr 30, 2026phase 2 completion121d agoBeijing Jishuitan Hospital — undisclosed anesthetic drug (Phase II Trial Completion)undisclosed anesthetic drug

Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Bone Fracture, Pain

full page →undisclosed anesthetic drug →source: globaldata

Apr 30, 2026phase 2 completion121d agoJetema Co Ltd — JTM-102 (Phase II Trial Completion)JTM-102

Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

full page →JTM-102 →source: globaldata

Apr 30, 2026phase 2 completion121d agoFirst Affiliated Hospital of Kunming Medical University — sugammadex (Phase II Trial Completion)sugammadex

Therapy area: Non Malignant Disorders, Women's Health. Indication: Unspecified Gynecological Disorders, Uterine Leiomyoma (Uterine Fibroids)

full page →sugammadex →source: globaldata

Apr 30, 2026phase 2 completion121d agoChinese Academy of Medical Sciences Plastic Surgery Hospital — recombinant type III humanized collagen (Phase II Trial Completion)recombinant type III humanized collagen

Therapy area: Dermatology. Indication: Crow Feet, Unspecified Dermatological Disorders, Wrinkles, Xerosis (Dry Skin)

full page →recombinant type III humanized collagen →source: globaldata

Apr 30, 2026phase 2 completion121d agoPolice General Hospital — acetaminophen (Phase II Trial Completion)acetaminophen ER

Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

full page →acetaminophen ER →source: globaldata

← prev

page 2 of 2

Week of Apr 27, 2026